337 related articles for article (PubMed ID: 37495688)
41. BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells.
Kurosu T; Fukuda T; Miki T; Miura O
Oncogene; 2003 Jul; 22(29):4459-68. PubMed ID: 12881702
[TBL] [Abstract][Full Text] [Related]
42. An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo.
Xing Y; Guo W; Wu M; Xie J; Huang D; Hu P; Zhou M; Zhang L; Zhang Q; Wang P; Wang X; Wang G; Wu H; Zhou C; Chen Y; Liu M; Yi Z; Sun Z
Cancer Lett; 2022 Mar; 529():100-111. PubMed ID: 34990752
[TBL] [Abstract][Full Text] [Related]
43. Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma.
Beck D; Zobel J; Barber R; Evans S; Lezina L; Allchin RL; Blades M; Elliott R; Lord CJ; Ashworth A; Porter AC; Wagner SD
J Biol Chem; 2016 Aug; 291(32):16686-98. PubMed ID: 27268052
[TBL] [Abstract][Full Text] [Related]
44. Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.
Willenbacher E; Willenbacher W; Weger R; Dominik W; Manzl C; Brunner A
Ann Hematol; 2020 Sep; 99(9):2125-2132. PubMed ID: 32613279
[TBL] [Abstract][Full Text] [Related]
45. EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis.
Béguelin W; Teater M; Gearhart MD; Calvo Fernández MT; Goldstein RL; Cárdenas MG; Hatzi K; Rosen M; Shen H; Corcoran CM; Hamline MY; Gascoyne RD; Levine RL; Abdel-Wahab O; Licht JD; Shaknovich R; Elemento O; Bardwell VJ; Melnick AM
Cancer Cell; 2016 Aug; 30(2):197-213. PubMed ID: 27505670
[TBL] [Abstract][Full Text] [Related]
46. Wilms' tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90.
Kuai Y; Gong X; Ding L; Li F; Lei L; Gong Y; Liu Q; Tan H; Zhang X; Liu D; Ren G; Pan H; Shi Y; Berberich-Siebelt F; Mao Z; Zhou R
Cell Commun Signal; 2018 Aug; 16(1):50. PubMed ID: 30143009
[TBL] [Abstract][Full Text] [Related]
47. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.
Li W; Gupta SK; Han W; Kundson RA; Nelson S; Knutson D; Greipp PT; Elsawa SF; Sotomayor EM; Gupta M
J Hematol Oncol; 2019 Jul; 12(1):73. PubMed ID: 31288832
[TBL] [Abstract][Full Text] [Related]
48. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
Polo JM; Dell'Oso T; Ranuncolo SM; Cerchietti L; Beck D; Da Silva GF; Prive GG; Licht JD; Melnick A
Nat Med; 2004 Dec; 10(12):1329-35. PubMed ID: 15531890
[TBL] [Abstract][Full Text] [Related]
49. CD137L and CD4 T cells limit BCL6-expressing pre-germinal center B cell expansion and BCL6-driven B cell malignancy.
Ding Z; Quast I; Yan F; Liao Y; Pitt C; O-Donnell K; Robinson MJ; Shi W; Kallies A; Zotos D; Tarlinton DM
Immunol Cell Biol; 2022 Oct; 100(9):705-717. PubMed ID: 35916066
[TBL] [Abstract][Full Text] [Related]
50. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
[TBL] [Abstract][Full Text] [Related]
51. Heterologous promoters fused to BCL6 by chromosomal translocations affecting band 3q27 cause its deregulated expression during B-cell differentiation.
Chen W; Iida S; Louie DC; Dalla-Favera R; Chaganti RS
Blood; 1998 Jan; 91(2):603-7. PubMed ID: 9427715
[TBL] [Abstract][Full Text] [Related]
52. A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.
Hatzi K; Jiang Y; Huang C; Garrett-Bakelman F; Gearhart MD; Giannopoulou EG; Zumbo P; Kirouac K; Bhaskara S; Polo JM; Kormaksson M; MacKerell AD; Xue F; Mason CE; Hiebert SW; Prive GG; Cerchietti L; Bardwell VJ; Elemento O; Melnick A
Cell Rep; 2013 Aug; 4(3):578-88. PubMed ID: 23911289
[TBL] [Abstract][Full Text] [Related]
53. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.
Chapuy B; McKeown MR; Lin CY; Monti S; Roemer MG; Qi J; Rahl PB; Sun HH; Yeda KT; Doench JG; Reichert E; Kung AL; Rodig SJ; Young RA; Shipp MA; Bradner JE
Cancer Cell; 2013 Dec; 24(6):777-90. PubMed ID: 24332044
[TBL] [Abstract][Full Text] [Related]
54. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
55. Detailed molecular analysis and evaluation of prognosis in cases with high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
Stengel A; Kern W; Meggendorfer M; Haferlach T; Haferlach C
Br J Haematol; 2019 Jun; 185(5):951-954. PubMed ID: 30460680
[No Abstract] [Full Text] [Related]
56. PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.
Franco R; Scognamiglio G; Valentino E; Vitiello M; Luciano A; Palma G; Arra C; La Mantia E; Panico L; Tenneriello V; Pinto A; Frigeri F; Capobianco G; Botti G; Cerchia L; De Chiara A; Fedele M
Oncotarget; 2016 Sep; 7(37):59158-59172. PubMed ID: 27494852
[TBL] [Abstract][Full Text] [Related]
57. The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis.
Baron BW; Anastasi J; Thirman MJ; Furukawa Y; Fears S; Kim DC; Simone F; Birkenbach M; Montag A; Sadhu A; Zeleznik-Le N; McKeithan TW
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2860-5. PubMed ID: 11854457
[TBL] [Abstract][Full Text] [Related]
58. Ikaros regulation of the BCL6/BACH2 axis and its clinical relevance in acute lymphoblastic leukemia.
Ge Z; Zhou X; Gu Y; Han Q; Li J; Chen B; Ge Q; Dovat E; Payne JL; Sun T; Song C; Dovat S
Oncotarget; 2017 Jan; 8(5):8022-8034. PubMed ID: 28030830
[TBL] [Abstract][Full Text] [Related]
59. Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl.
Bai M; Skyrlas A; Agnantis NJ; Kamina S; Tsanou E; Grepi C; Galani V; Kanavaros P
Mod Pathol; 2004 Jul; 17(7):847-56. PubMed ID: 15073604
[TBL] [Abstract][Full Text] [Related]
60. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.
Richter A; Sender S; Lenz A; Schwarz R; Hinz B; Knuebel G; Sekora A; Murua Escobar H; Junghanss C; Roolf C
BMC Cancer; 2020 Mar; 20(1):184. PubMed ID: 32131762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]